Futibatinib 4 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 4 mg

Reference Brands: Lytgobi (USA)

Category: Oncology Cancer Care

Futibatinib 4 mg film-coated tablets, an irreversible FGFR1-4 inhibitor for previously treated FGFR2-rearranged intrahepatic cholangiocarcinoma. For hospital oncology pharmacies and licensed importers.

Product Description:

Futibatinib is a covalent inhibitor of all four fibroblast growth factor receptors. It forms a permanent bond with a cysteine in the receptor's kinase pocket, so the block lasts until the cell makes new receptor protein, which sets it apart from the reversible members of this class. It is supplied in one strength only, a 4 mg film-coated tablet. The daily dose is made up of several tablets taken together, and a dose reduction simply means taking fewer of them.

It is approved for adults with previously treated, unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma carrying an FGFR2 fusion or other rearrangement. It is taken once a day, every day, with or without food, swallowed whole. Raised blood phosphate is the most frequent laboratory change, so phosphate is tested regularly and managed as the label sets out. Retinal pigment epithelial detachment can occur, so eye checks are scheduled at baseline and during therapy. Strong combined CYP3A and P-gp inhibitors or inducers should not be co-prescribed.

Sourcing notes. Registration is limited to a few markets so far, so many orders are placed for individual patients under special-access rules. Because the dose is built from 4 mg tablets, count monthly need in tablets, not packs. The tablets ship and store at room temperature. Request the batch CoA, proof of an authorised supply chain and, for registered imports, the GMP certificate and CoPP. Treating centres confirm the FGFR2 result from a validated test before ordering. Keep it in original serialised packs with the approved leaflet.